Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Hepatic insulin signalling involves insulin receptor substrates (Irs) 1/2, and is normally associated with the inhibition of gluconeogenesis and activation of lipogenesis. In diabetes and obesity, insulin no longer suppresses hepatic gluconeogenesis, while continuing to activate lipogenesis, a state referred to as ‘selective insulin resistance’. Here, we show that ‘selective insulin resistance’ is caused by the differential expression of Irs1 and Irs2 in different zones of the liver. We demonstrate that hepatic Irs2-knockout mice develop ‘selective insulin resistance’, whereas mice lacking in Irs1, or both Irs1 and Irs2, develop ‘total insulin resistance’. In obese diabetic mice, Irs1/2-mediated insulin signalling is impaired in the periportal zone, which is the primary site of gluconeogenesis, but enhanced in the perivenous zone, which is the primary site of lipogenesis. While hyperinsulinaemia reduces Irs2 expression in both the periportal and perivenous zones, Irs1 expression, which is predominantly in the perivenous zone, remains mostly unaffected. These data suggest that ‘selective insulin resistance’ is induced by the differential distribution, and alterations of hepatic Irs1 and Irs2 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SREBP1c, which is controlled by both insulin signaling and insulin-independent pathways [2,20,75]”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The concept of hepatic zonation of insulin signaling components can also help explain the paradoxical coexistence of increased hepatic glucose output and increased hepatic lipogenesis in MASLD [15,20].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Studies suggest that IRS1 and IRS2 have distinct roles in regulating hepatic lipid metabolism [20,30,97].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, DNL is markedly decreased in LIRS1KO mice but not in LIRS2KO mice.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“This leads to impaired insulin signaling in gluconeogenic zones, resulting in insufficient suppression of HGP and thus contributing to systemic hyperglycemia.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [20]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance
Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80210-5 · Cited by 1,342
Self-citationMichael, M. D., Kulkarni, R. N., Postic, C., Previs, S. F., Shulman, G. I., Magnuson, M. A., & Kahn, C. R. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00015-8 · Cited by 1,296
Postic, C., & Girard, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,204
Selective versus Total Insulin Resistance: A Pathogenic Paradox
Brown, M. S., & Goldstein, J. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.009 · Cited by 965
SHIMOMURA, I. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00009-5 · Cited by 855
Shimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., & Goldstein, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118951 · Cited by 816
Research works printed but not linked: 1
- Benhamouche, S. et al. Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev. Cell. 10, 759–770 (2006). · DOI · Paper page
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
The PI3K/AKT Pathway in Obesity and Type 2 Diabetes
Huang, X., Liu, G., Guo, J., & Su, Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27173 · Cited by 1,673
“And recent study finds Irs2-knockout mice develop ‘selective insulin resistance’, whereas mice lacking in Irs1, or both Irs1 and Irs2, develop ‘total insulin resistance’, which indicates the IRS 1/2 are the cause of insulin selective resistance [109]; in the second, hepatic insulin signalling remains intact but the ce…”
BackgroundSREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology
Shimano, H., & Sato, R. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.91 · Cited by 1,174
Biochemical and cellular properties of insulin receptor signalling
Haeusler, R. A., McGraw, T. E., & Accili, D. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.89 · Cited by 739
Pathophysiology of Diabetic Dyslipidemia
Hirano, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17023 · Cited by 552
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021) · Advanced Science · doi:10.1002/advs.202100275 · Cited by 525
Role of Insulin Resistance in MAFLD
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084156 · Cited by 448
Self-citationResolving the paradox of hepatic insulin resistance
Santoleri, D., & Titchenell, P. M. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.10.016 · Cited by 336
“Knockout of multiple insulin-receptor substrates prevents activation of the pathway in response to insulin, leading to insulin resistance and hyperglycemia, but not hepatic steatosis.(19,20) PIP3 initiates recruitment of Akt (named as such when it was discovered to be the oncogene responsible for thymoma in Ak mice, a…”
BackgroundBo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Obesity and ageing: Two sides of the same coin
Tam, B. T., Morais, J. A., & Santosa, S. (2020) · Obesity Reviews · doi:10.1111/obr.12991 · Cited by 253
“Moreover, obesity partially impairs the insulin signaling in liver by relaxing its inhibition of gluconeogenesis and maintaining the activation of lipogenesis through the differential expression of IRS-1 and IRS-2 in periportal and perivenous zones of liver.(184) In obesity and ageing, the peripheral insulin resistanc…”
BackgroundInsulin Resistance and Diabetes Mellitus in Alzheimer’s Disease
Burillo, J., Marqués, P., Jiménez, B., González-Blanco, C., Benito, M., & Guillén, C. (2021) · Cells · doi:10.3390/cells10051236 · Cited by 225
Hepatic lipid droplet homeostasis and fatty liver disease
Seebacher, F., Zeigerer, A., Kory, N., & Krahmer, N. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.04.011 · Cited by 190
“Some researchers have suggested that differential hepatic distribution and alterations of IRS1 and IRS2 expression play important roles in this process (101, 102).”
BackgroundKubota, T., Kubota, N., & Kadowaki, T. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.004 · Cited by 169
“Tanaka et al., 1997; Bl€uher et al., 2002; Kubota et al., 2016).”
BackgroundSelf-citationHepatic transcriptional responses to fasting and feeding
Bideyan, L., Nagari, R., & Tontonoz, P. (2021) · Genes & Development · doi:10.1101/gad.348340.121 · Cited by 126
“Kubota et al. (2016) described that in obese mice, insulin signaling is impaired in the periportal zone, the primary site for gluconeogenesis, as Irs2 expression is reduced there.”
BackgroundBesse-Patin, A., Jeromson, S., Levesque-Damphousse, P., Secco, B., Laplante, M., & Estall, J. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815150116 · Cited by 124
“T-Cell Factor 4 (TCF4/TCF7L2) regulates Irs1 expression (22, 23), binds to the Irs2 promoter (24), and is a major player in hepatic metabolic zonation, which also impacts IRS expression (22).”
BackgroundInfluentialTaheri, R., Mokhtari, Y., Yousefi, A., & Bashash, D. (2024) · Cell Biology International · doi:10.1002/cbin.12189 · Cited by 126
“A recent study has revealed that different hepatic expression patterns of IRS1 and IRS2 might be responsible for this phenomenon (Kubota et al., 2016).”
Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers
Honma, M., Sawada, S., Ueno, Y., Murakami, K., Yamada, T., Gao, J., Kodama, S., Izumi, T., Takahashi, K., Tsukita, S., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0062-9 · Cited by 108
“In animal studies using obese models such as mice fed a high-fat diet [9, 11, 35], ob/ob mice [7, 36] and Zucker fatty rats [30], levels of IRS-2 mRNA were shown to be decreased in contrast to those of IRS-1.”
BackgroundInfluentialHepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease
ter Horst, K. W., Vatner, D. F., Zhang, D., Cline, G. W., Ackermans, M. T., Nederveen, A. J., Verheij, J., Demirkiran, A., van Wagensveld, B. A., Dallinga-Thie, G. M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1644 · Cited by 88
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“In a liver-specific IRS KO mouse model study, liver-specific IRS2 KO (LIRS2KO) mice, but not liver-specific IRS1 KO (LIRS1KO) mice, developed hepatic steatosis on an HFD, while LIRS1KO mice were protected from steatosis [20].”
InfluentialGong, H., Gao, J., Wang, Y., Luo, Q.-W., Guo, K., Ren, F., & Mao, X. (2020) · Journal of Dairy Science · doi:10.3168/jds.2019-17513 · Cited by 90
Wang, Z., Zhu, S., Jia, Y., Wang, Y., Kubota, N., Fujiwara, N., Gordillo, R., Lewis, C., Zhu, M., Sharma, T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.014 · Cited by 72
Self-citationKrause, C., Geißler, C., Tackenberg, H., Gammal, A. T. E., Wolter, S., Spranger, J., Mann, O., Lehnert, H., & Kirchner, H. (2020) · Diabetologia · doi:10.1007/s00125-020-05212-6 · Cited by 75
Insulin: Trigger and Target of Renal Functions
Pina, A. F., Borges, D. O., Meneses, M. J., Branco, P. Q., Birne, R., Vilasi, A. D., & Macedo, M. P. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00519 · Cited by 68
Dysregulation of hepatic metabolism with obesity: factors influencing glucose and lipid metabolism
Nagarajan, S. R., Cross, E., Sanna, F., & Hodson, L. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s0029665121003761 · Cited by 71
“In support of this concept, protein regulation of metabolic pathways may be additionally governed by distinct insulin sensitivity thresholds((88)), multiple phosphorylation sites((89)) and differential expression patterns((90,91)).”
The Influence of Different Types of Diabetes on Vascular Complications
Wei, J., Tian, J., Tang, C. C., Fang, X., Miao, R., Wu, H., Wang, X., & Tong, X. (2022) · Journal of Diabetes Research · doi:10.1155/2022/3448618 · Cited by 86
“Insulin receptor substrates include insulin receptor substrate-1 (Irs1) and insulin receptor substrate-2 (Irs2), and Irs1 and Irs2 double knockout mice developed liver insulin resistance, which resulted in hyperinsulinemia and diabetes [39, 40].”
BackgroundThe role of adipose tissue dysfunction in hepatic insulin resistance and T2D
Sancar, G., & Birkenfeld, A. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0115 · Cited by 79
TFEB is a central regulator of the aging process and age-related diseases
Abokyi, S., Ghartey‐Kwansah, G., & Tse, D. Y. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101985 · Cited by 64
Hormonal regulation of metabolism—recent lessons learned from insulin and estrogen
Tao, Z., & Cheng, Z. (2023) · Clinical Science · doi:10.1042/cs20210519 · Cited by 72
Erlandsson, M. C., Silfverswärd, S. T., Nadali, M., Turkkila, M., Svensson, M. N. D., Jonsson, I., Andersson, K., & Bokarewa, M. I. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.002 · Cited by 65
Sugiyama, M., Kikuchi, A., Misu, H., Igawa, H., Ashihara, M., Kushima, Y., Honda, K., Suzuki, Y., Kawabe, Y., Kaneko, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194798 · Cited by 52
Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status
Hu, C., Chen, Y., Yin, X., Xu, R., Yin, C., Wang, C., & Zhao, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02098-3 · Cited by 87
Role of insulin receptor substrates in the progression of hepatocellular carcinoma
Sakurai, Y., Kubota, N., Takamoto, I., Obata, A., Iwamoto, M., Hayashi, T., Aihara, M., Kubota, T., Nishihara, H., & Kadowaki, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-03299-3 · Cited by 51
Self-citationMASLD in children: integrating epidemiological trends with mechanistic and translational advances
Schwimmer, J. B., Biddinger, S. B., & Ibrahim, S. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186422 · Cited by 57
Fathers’ preconception smoking and offspring DNA methylation
Kitaba, N. T., Knudsen, G. T. M., Johannessen, A., Rezwan, F. I., Malinovschi, A., Oudin, A., Benediktsdóttir, B., Martino, D., González, F. J. C., Gómez, L. P., et al. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01540-7 · Cited by 51
Matsukawa, T., Yagi, T., Uchida, T., Sakai, M., Mitsushima, M., Naganuma, T., Yano, H., Inaba, Y., Inoue, H., Yanagida, K., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.161282 · Cited by 48
Self-citationThe hepatocyte insulin receptor is required to program the liver clock and rhythmic gene expression
Fougeray, T., Polizzi, A., Régnier, M., Fougerat, A., Ellero‐Simatos, S., Lippi, Y., Smati, S., Lasserre, F., Tramunt, B., Huillet, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110674 · Cited by 43
“, 2019a), including activation of lipogenesis and inhibition of gluconeogenesis (Brown and Goldstein, 2008; Kubota et al., 2016; Li et al., 2010; Titchenell et al., 2017).”
BackgroundVEGFB ameliorates insulin resistance in NAFLD via the PI3K/AKT signal pathway
Li, Y., Li, W., Zhu, X., Xu, N., Meng, Q., Jiang, W., Zhang, L., Yang, M., Xu, F., & Li, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05621-w · Cited by 42
“Insulin receptor (INSR) and insulin receptor substrate (IRS), the upstream proteins of PI3K, were activated by the increase of insulin release [12].”
BackgroundEssential Minerals and Metabolic Adaptation of Immune Cells
Alghamdi, M. A., Gutierrez, J., & Komarnytsky, S. (2022) · Nutrients · doi:10.3390/nu15010123 · Cited by 52
“On the molecular level, the processes are mediated in part by increased de novo lipogenesis in the liver, reduced fat oxidation in mitochondria, accumulation of toxic ceramides and diacylglycerides, and activation of mTOR that ultimately degrade the insulin receptor substrate-1 (IRS-1) substrate and lead to malfunctio…”
BackgroundSDF-1 Is an Autocrine Insulin-Desensitizing Factor in Adipocytes
Shin, J., Fukuhara, A., Onodera, T., Kita, S., Yokoyama, C., Otsuki, M., & Shimomura, I. (2018) · Diabetes · doi:10.2337/db17-0706 · Cited by 36
“IRS-1 is responsible for insulin-mediated suppression of gluconeogenesis in the liver (43) and insulin-mediated glucose uptake in the skeletal muscle (44).”
BackgroundMatsumoto, M., Yashiro, H., Ogino, H., Aoyama, K., Nambu, T., Nakamura, S., Nishida, M., Wang, X., Erion, D. M., & Kaneko, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228212 · Cited by 37
“Furthermore, it was reported that the activation of lipogenesis, which is the physiological action of insulin in the liver, remains in animal models fed high fat diets [51] and in NAFLD patients [52] despite systemic insulin resistance.”
BackgroundOchiai, T., Sano, T., Nagayama, T., Kubota, N., Kadowaki, T., Wakabayashi, T., & Iwatsubo, T. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105510 · Cited by 36
“For example, in the liver, differential expression patterns of IRS-1 and IRS-2 within the organ have been reported to cause functional differences in insulin signaling (Kubota et al., 2016).”
BackgroundSelf-citationType 2 diabetes – unmet need, unresolved pathogenesis, mTORC1-centric paradigm
Bar‐Tana, J. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09545-w · Cited by 44
Davies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 61
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 40
“After being transported by the tricarboxylate transport system, cytoplasmic acetyl-CoA is not only a substrate for FAs and cholesterol synthesis, but also for both histone and liver X receptor (LXR) α acetylation, both increasing SREBP-1c expression, and indirectly regulating DNL [60–62].”
BackgroundInfluentialInsulin resistance in cancer risk and prognosis
Jacobo-Tovar, E., Medel-Sánchez, A., Durán-Castillo, C., & Guardado‐Mendoza, R. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.006 · Cited by 36
Zhang, J., Chen, Y., Liu, C., Li, L., & Li, P. (2020) · Journal of Diabetes Research · doi:10.1155/2020/1080152 · Cited by 31
“In the case of complete failure of hepatic insulin receptor signaling, increased gluconeogenesis and the phenomenon of reduced lipogenesis will coexist in the liver, a situation known as “overall insulin resistance” [30].”
BackgroundAlbumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease
Chikamatsu, M., Watanabe, H., Shintani, Y., Murata, R., Miyahisa, M., Nishinoiri, A., Imafuku, T., Takano, M., Arimura, N., Yamada, K., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.039 · Cited by 29
Insulin activates hepatic Wnt/β-catenin signaling through stearoyl-CoA desaturase 1 and Porcupine
Cabrae, R., Dubuquoy, C., Caüzac, M., Morzyglod, L., Guilmeau, S., Noblet, B., Fève, B., Postic, C., Burnol, A., & Moldes, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-61869-4 · Cited by 26
Spatial regulation of glucose and lipid metabolism by hepatic insulin signaling
He, B., Copps, K. D., Stöhr, O., Liu, B., Hu, S., Joshi, S., Haigis, M. C., White, M. F., Zhu, H., & Tao, R. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.03.015 · Cited by 31
Kakazu, E., Sano, A., Morosawa, T., Inoue, J., Ninomiya, M., Iwata, T., Nakamura, T., Takai, S., Sawada, S., Katagiri, H., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13346 · Cited by 27
Yang, Z., Dong, H., Gao, Y., Liu, S., Chen, L., Ni, G., Guo, X., Wang, M., Wang, C., Chen, Y., et al. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.3c06468 · Cited by 36
Obesity and Insulin Resistance: A Review of Molecular Interactions
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Current Molecular Medicine · doi:10.2174/1566524020666200812221527 · Cited by 36
“For example, it may reduce Glut-4 expression/localization [125, 127-129], induces IRs polymorphism and disturb its phosphorylation/activity [127, 130, 131] or impair PI3/Akt signaling pathways [127, 132, 133].”
Njume, C., Donkor, O. N., & McAinch, A. J. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.12.001 · Cited by 24
Kakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 28
VAPB-mediated ER-targeting stabilizes IRS-1 signalosomes to regulate insulin/IGF signaling
Gao, X. K., Sheng, Z. K., Lu, Y. H., Sun, Y. T., Rao, X. S., Shi, L. J., Cong, X. X., Chen, X., Wu, H. B., Huang, M., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00576-6 · Cited by 20
Manzano‐Núñez, F., Arámbul-Anthony, M. J., Albiñana, A. G., Leal‐Tassias, A., Umanzor, C. A., Gascó, I. B., Herrera, A., Vila, J. F., Burks, D. J., & Noon, L. A. (2019) · PLoS Biology · doi:10.1371/journal.pbio.2006972 · Cited by 21
Physiological and pathophysiological actions of insulin in the liver
Kubota, N., Kubota, T., & Kadowaki, T. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0192 · Cited by 19
“We previously identified that hepatic zona‐ tion of IRS-1 plays a crucial role in selective insulin resistance [115].”
Self-citationMilhem, F., & Komarnytsky, S. (2023) · Metabolites · doi:10.3390/metabo13091016 · Cited by 26
“Inflammation of the adipose tissues promotes de novo lipogenesis, reduces fat oxidation in mitochondria, and accumulates ceramides and diacylglycerides in the metabolically active cells that inhibit insulin signaling [126].”
Lipogenesis and MASLD: re-thinking the role of SREBPs
Nakagawa, H. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04052-w · Cited by 25
“Although the molecular mechanisms underlying selective insulin resistance are not yet fully elucidated, Kubota et al. addressed this issue by focusing on the zonal differences in IRS expression (Kubota et al. 2016, 2017).”
Kurtz, R., Anderman, M. F., & Shepard, B. D. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00275.2020 · Cited by 18
Insulin Hypersecretion as Promoter of Body Fat Gain and Hyperglycemia
Mittendorfer, B., Johnson, J. D., Solinas, G., & Jansson, P. (2024) · Diabetes · doi:10.2337/dbi23-0035 · Cited by 23
Takatani, T., Shirakawa, J., Shibue, K., Gupta, M. K., Kim, H., Lu, S., Hu, J., White, M. F., Kennedy, R. T., & Kulkarni, R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100646 · Cited by 17
“, alpha cells) and other metabolic organs similar to reports in other tissue-specific models (31) and requires further study.”
BackgroundThe role of glycolysis in MASLD development: Pathogenesis and therapeutic strategies
Shang, Y., Sun, Q., Xin, X., Wang, Z., Gao, S., Lin, R., Hu, Y., Wang, X., & Feng, Q. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107990 · Cited by 18
Olatunde, A., Mohammed, A., Ibrahim, M. A., & Shuaibu, M. N. (2020) · Phytomedicine Plus · doi:10.1016/j.phyplu.2020.100003 · Cited by 14
Tao, R., Stöhr, O., Wang, C., Qiu, W., Copps, K. D., & White, M. F. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101703 · Cited by 20
“In contrast, LDKO mice fed HFD were indistinguishable from chow-fed LDKO mice (Figure 1A,B) [17,33,38].”
MethodEffects of Training Status and Exercise Mode on Global Gene Expression in Skeletal Muscle
Bizjak, D. A., Zügel, M., Treff, G., Winkert, K., Jerg, A., Hudemann, J., Mooren, F. C., Krüger, K., Niess, A. M., & Steinacker, J. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212578 · Cited by 16
“It is assumed that IRS1/IRS2 dysregulation plays a crucial role in the development of obesity and diabetes [41,42].”
BackgroundHayashi, T., Kubota, T., Inoue, M., Takamoto, I., Aihara, M., Sakurai, Y., Wada, N., Miki, T., Yamauchi, T., Kubota, N., et al. (2021) · Diabetes · doi:10.2337/db20-0482 · Cited by 13
Self-citationZhang, Z., Cui, M., Wang, H., Yuan, W., Liu, Z., Gao, H., Guan, X., Chen, X., Xie, L., He, Y., et al. (2025) · Environmental Pollution · doi:10.1016/j.envpol.2025.125771 · Cited by 11
Hayashi, H., Sawada, K., Tanaka, H., Muro, K., Hasebe, T., Nakajima, S., Okumura, T., & Fujiya, M. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16337 · Cited by 10
“20,21,23,26 This differential expression of IRS-1 and IRS-2 can induce selective hepatic insulin resistance.”
BackgroundHigh-fat-diet-induced hepatic insulin resistance per se attenuates murine de novo lipogenesis
Goedeke, L., Strober, J. W., Suh, R., Paolella, L. M., Li, X., Rogers, J. C., Petersen, M. C., Nasiri, A. R., Casals, G., Kahn, M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111175 · Cited by 15
“17 Nevertheless, in the present studies, (i) restoration of near-normal levels of lipogenesis in whole-body insulin-resistant mice, along with (ii) the steady increase in lipogenesis seen with increased substrate flux during the hyperinsulinemic-hyper-glycemic clamps regardless of degree of hepatic…”
Liver metabolism: the pathways underlying glucose utilization and production
Nogueira‐Ferreira, R., Oliveira, P. F., & Ferreira, R. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91704-9.00018-5 · Cited by 16
Li, D., Cao, J., Zhang, J., Mu, T., Wang, R., Li, H., Tang, H., Chen, L., Lin, X., Peng, X., et al. (2023) · Foods · doi:10.3390/foods12132627 · Cited by 10
“Under normal circumstances, insulin stimulates glucose uptake and glycogen synthesis in hepatocytes, while insulin resistance affects glucose storage (glycogenesis) and glucose output (gluconeogenesis), thereby causing lipid metabolic disorders and type 2 diabetes [44,45].”
BackgroundDanoy, M., Poulain, S., Jellali, R., Scheidecker, B., Tauran, Y., Leduc, M., Bruce, J., Kim, S. H., Kido, T., Miyajima, A., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13893 · Cited by 10
“In addition, extraction of either the nitrogen zonation pattern (urea synthesis profile in portal area and glutamine secretion in the perivenous area(66)) nor the complexity of insulin/glucagon profile along the sinusoid could not be performed.(68,69)”
BackgroundAnalysis of Insulin Resistance in Nonalcoholic Steatohepatitis
Kim, H., Zhang, D., Song, Z., Tong, X., & Zhang, K. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2128-8_18 · Cited by 8
Adipose tissue macrophages in remote modulation of hepatic glucose production
Tao, Y., Jiang, Q., & Wang, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.998947 · Cited by 9
“TNF-a in association with insulin resistance: Pathological stimulation of HGP Insulin resistance is the major cause and typical feature of type 2 diabetes, which is closely associated with abnormal hepatocyte gluconeogenesis that contributes to enhanced HGP (16, 25, 26).”
BackgroundExenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
Bai, C., Wang, Y., Niu, Z., Guan, Y., Huang, J., Nian, X., Zuo, F., Zhao, J., Kazumi, T., & Wu, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1012904 · Cited by 7
“The expression levels of pIRS2(S731) protein in the adipose tissue of high-fat diet-induced diabetic adipose tissue was significantly higher than that of the normal diet control group, but the expression levels of IRS2 protein in the liver and adipose tissue of the diabetic adipose tissue was lower than that of the co…”
Baya, N. A., Sur‐Erdem, İ., Venkatesh, S. S., Reibe, S., Charles, P. D., Navarro‐Guerrero, E., Hill, B., Lassen, F. H., Claussnitzer, M., Palmer, D. S., et al. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.08.013 · Cited by 9
Méndez-Giménez, L., Becerril, S., Moncada, R., Valentí, V., Fernández, S., Ramírez, B., Catalán, V., Gómez‐Ambrosi, J., Soveral, G., Malagón, M. M., et al. (2017) · Obesity Surgery · doi:10.1007/s11695-016-2532-2 · Cited by 8
Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance
Tao, R., Stöhr, O., Tok, O., Andrés-Hernando, A., Qiu, W., He, B., Wang, C., Grøntved, L., Burant, C., Hui, S. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66296-5 · Cited by 7
Iwamoto, M., Kubota, T., Sakurai, Y., Wada, N., Shioda, S., Yamauchi, T., Kadowaki, T., & Kubota, N. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.971 · Cited by 6
Self-citationTang, S., Zheng, W., Ren, X., Song, S., & Ai, C. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.105436 · Cited by 5
Somatic genomics as a discovery engine for biomedicine
Brunner, S. F., Martincorena, I., Mannino, G., Fox, C. S., Stratton, M. R., Rubens, J. R., Campbell, P. J., & Zhu, H. (2026) · Cell · doi:10.1016/j.cell.2026.01.032 · Cited by 9
“106,107 These types of conflicts underscore a central challenge of somatic genetics—the inability to predict patient-level phenotypes based on selection strength alone.”
Midlobular zone 2 hepatocytes: A gatekeeper of liver homeostasis
Kubota, N., Kubota, T., & Kadowaki, T. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.005 · Cited by 8
Self-citationMakena, W., Iliya, A. I., Hambolu, J. O., Timbuak, J. A., Umana, U. E., & Dibal, N. I. (2021) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2021-0378 · Cited by 6
Sakurai, Y., Kubota, N., Takamoto, I., Wada, N., Aihara, M., Hayashi, T., Kubota, T., Hiraike, Y., Sasako, T., Nakao, H., et al. (2023) · Diabetes · doi:10.2337/db23-0150 · Cited by 7
Self-citationRodrigues, J. S., Faria‐Pereira, A., Camões, S. P., Serras, A. S., Morais, V. A., Ruas, J. L., & Miranda, J. P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043543 · Cited by 6
“Irs2 expression increases in the fasting state and immediately decreases after food intake which is accompanied by an increase in insulin blood levels (46).”
BackgroundJiang, S., Zhai, L., Shao, Y., Sun, F., & Liu, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1743899 · Cited by 9
El-Said, K. S., Noser, A. A., & Mohamed, A. E.-S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108696 · Cited by 4
MASLD In Children - A Distinct Phenotype?
Barbhuiya, P. A., & Pathak, M. P. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00698-4 · Cited by 4
Unraveling the mysteries of hepatic insulin signaling: deconvoluting the nuclear targets of insulin
Kitamoto, T., & Accili, D. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej23-0150 · Cited by 4
Matsushita, M., Awazawa, M., Kobayashi, N., Ikushima, Y. M., Soeda, K., Tamura‐Nakano, M., Muratani, M., Kobayashi, K., Blüher, M., Brüning, J. C., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.12.008 · Cited by 4
Self-citationChoi, Y., Song, J. E., Lim, S.-H., & Song, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1663958 · Cited by 3
“Another hypothesis suggests that hyperinsulinemia-induced hepatic lipogenesis may be a key driver of this metabolic dysregulation (6).”
Insulin as an Accelerator and Brake of Aging: From Molecular Landscape to Clinical Interventions
Chen, S., Sun, X., & Zhang, Y. (2025) · Comprehensive physiology · doi:10.1002/cph4.70079 · Cited by 4
“At the same time, IRS1 remains predominantly unchanged, establishing IRS2 degradation as a key mechanism underlying selective hepatic IR (Kubota et al. 2016).”
Narimatsu, Y., Kato, M., Ukena, K., Furumitsu, M., & Ukena, K. (2025) · Peptides · doi:10.1016/j.peptides.2025.171376 · Cited by 5
Elfaki, I., Mir, R., Almowallad, S. J., Al-Massabi, R. F., Albalawi, W., Albalawi, A. D., Bhat, A. A., Barnawi, J., Tayeb, F. J., Jalal, M. M., et al. (2025) · Medicina · doi:10.3390/medicina61061017 · Cited by 3
“It has been suggested that in obesity and T2DM the IRS2-mediated insulin signaling is impaired in hepatocytes [66].”
Potential role of microRNAs in selective hepatic insulin resistance: From paradox to the paradigm
Palihaderu, P. A. D. S., Mendis, B. I. L. M., Premarathne, J. M. K. J. K., Dias, W. K. R. R., Yeap, S. K., Ho, W. Y., Dissanayake, A. S., Rajapakse, I. H., Karunanayake, P., Senarath, U., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1028846 · Cited by 3
“The higher expressions of miR-125b were inversely correlated with the insulin-mediated AKT and GSK3b phosphorylation and positively related to the expression levels of PEPCK and G6Pase genes (54).”
BackgroundInfluentialWestcott, F., Nagarajan, S. R., Parry, S. A., Savic, D., Green, C., Marjot, T., Johnson, E. M., Cornfield, T., Mózes, F. E., O’Rourke, P., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae123 · Cited by 6
“3-5 The distinction between selective and total hepatic IR derives from murine studies with liver-specific insulin receptor knockout that displayed both impaired suppression of glucose production and impaired stimulation of DNL.”
Liu, Q., & Niu, C.-Y. (2019) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v27.i19.1171 · Cited by 3
ER Stress Response Failure and Steatohepatitis Comorbid with Diabetes
Sasako, T., & Ueki, K. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100054 · Cited by 3
Self-citationSushma, B. J., Parashar, S., Tomar, B. S., Meena, A., & Priyanka, B. (2025) · Biochemistry Research International · doi:10.1155/bri/4060832 · Cited by 2
Metadata
- Authors
- Kubota, N., Kubota, T., Kajiwara, E., Iwamura, T., Kumagai, H., Watanabe, T., Inoue, M., Takamoto, I., Sasako, T., Kumagai, K., Kohjima, M., Nakamuta, M., Moroi, M., Sugi, K., Noda, T., Terauchi, Y., Ueki, K., & Kadowaki, T.
- Affiliations
- National Institute of Biomedical Innovation, Health and Nutrition (JP)
- Toho University (JP)
- The University of Tokyo (JP)
- Hokkaido University (JP)
- Tokyo Medical University (JP)
- National Kyushu Medical Center (JP)
- Japanese Foundation For Cancer Research (JP)
- Yokohama City University (JP)
- Corresponding author
- Kubota, Naoto
- Kadowaki, Takashi
- ORCID
- Venue
- Nature Communications
- Published
- 2016-10-06
- Volume
- 7
- Issue
- 1
- Pages
- 12977-12977
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5059684
- OpenAlex
- W2529090544
- Cited by
- 143
- References
- 46
- Citations by year
- 2026: 22 · 2025: 19 · 2024: 17 · 2023: 19 · 2022: 11 · 2021: 17 · 2020: 15 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 1
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Takeda Science Foundation
- Ministry of Education, Culture, Sports, Science and Technology (20229008, 18209033, 19591037, 16209030, 21390279)
- Ono Medical Research Foundation
- Japan Society for the Promotion of Science (16K15488, 16H05329, 26000012)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- IRS-1, insulin receptor substrate 2, liver zonation, periportal zone, perivenous zone, gluconeogenesis, lipogenesis, hyperinsulinemia, obesity, diabetes mellitus
- MeSH terms
- Animals, Cell Nucleus, Diabetes Mellitus, Diabetes Mellitus, Experimental, Gluconeogenesis, Homeostasis, Humans, Hyperinsulinism, Insulin, Insulin Resistance, Liver, Male, Mice, Inbred C57BL, Obesity, Receptor, Insulin, Signal Transduction, Antigens, CD, Mice, Knockout, Mice, Insulin Receptor Substrate Proteins, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.